{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:07:49Z","timestamp":1792555669702,"version":"4.5.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001960","name":"American Society for Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001960","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.prro.2023.09.007","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T04:17:42Z","timestamp":1704255462000},"page":"47-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Radiation Therapy Summary of the AUA\/ASTRO Guideline on Clinically Localized Prostate Cancer"],"prefix":"10.1016","volume":"14","author":[{"suffix":"Jr","given":"Curtiland","family":"Deville","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia C.","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosj","family":"Yamoah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Vapiwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2023.09.007_bib0001","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically localized prostate cancer: AUA\/ASTRO Guideline, part II: Principles of active surveillance, principles of surgery, and follow-up","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2023.09.007_bib0002","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO Guideline, part I: Introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2023.09.007_bib0003","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/JU.0000000000002759","article-title":"Clinically localized prostate cancer: AUA\/ASTRO Guideline. Part III: Principles of radiation and future directions","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2023.09.007_bib0004","series-title":"Management of Clinically Localized Prostate Cancer: A Systematic Evidence Review","author":"Chou","year":"2022"},{"key":"10.1016\/j.prro.2023.09.007_bib0005","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/JU.0000000000001578","article-title":"Therapies for clinically localized prostate cancer: A comparative effectiveness review","volume":"205","author":"Wilt","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2023.09.007_bib0006","unstructured":"Program EHC. Systematic review: Therapies for clinically localized prostate cancer. Agency for Healthcare Research and Quality. Accessed March 7, 2023. https:\/\/effectivehealthcare.ahrq.gov\/products\/prostate-cancer-therapies\/report"},{"key":"10.1016\/j.prro.2023.09.007_bib0007","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa1615869","article-title":"Follow-up of prostatectomy versus observation for early prostate cancer","volume":"377","author":"Wilt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2023.09.007_bib0008","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.crad.2007.05.022","article-title":"The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: A meta-analysis","volume":"63","author":"H\u00f6vels","year":"2008","journal-title":"Clin Radiol"},{"key":"10.1016\/j.prro.2023.09.007_bib0009","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1470-2045(08)70203-1","article-title":"MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: A prospective multicohort study","volume":"9","author":"Heesakkers","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2023.09.007_bib0010","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s11547-018-0929-9","article-title":"(68)Ga-PSMA-PET: Added value and future applications in comparison to the current use of choline-PET and mpMRI in the workup of prostate cancer","volume":"123","author":"Malaspina","year":"2018","journal-title":"Radiol Med"},{"key":"10.1016\/j.prro.2023.09.007_bib0011","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eururo.2022.10.024","article-title":"Incorporating prostate-specific membrane antigen positron emission tomography in management decisions for men with newly diagnosed or biochemically recurrent prostate cancer","volume":"83","author":"Bukavina","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2023.09.007_bib0012","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2023.09.007_bib0013","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2967\/jnumed.120.251751","article-title":"Disparities in PET imaging for prostate cancer at a tertiary academic medical center","volume":"62","author":"Bucknor","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1016\/j.prro.2023.09.007_bib0014","unstructured":"National Comprehensive Cancer Network (NCCN) Guidelines version 1. 2023. Prostate cancer. Accessed March 6, 2023.https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf. Accessed March 6, 2023."},{"key":"10.1016\/j.prro.2023.09.007_bib0015","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.eururo.2018.06.025","article-title":"Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a randomized multicenter prospective trial","volume":"75","author":"Klotz","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2023.09.007_bib0016","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2023.09.007_bib0017","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1200\/JCO.22.00645","article-title":"Adjuvant radiation for pathologically node-positive prostate cancer: Evidence when early salvage may not be early enough","volume":"40","author":"Cao","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.09.007_bib0018","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): A randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2023.09.007_bib0019","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): A randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2023.09.007_bib0020","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): A randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2023.09.007_bib0021","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ijrobp.2020.12.022","article-title":"Adjuvant versus early salvage radiation therapy after radical prostatectomy for men with adverse pathologic features-the debate continues","volume":"109","author":"Chen","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.09.007_bib0022","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.juro.2018.01.002","article-title":"Clinically localized prostate cancer: AUA\/ASTRO\/SUO Guideline. Part II: recommended approaches and details of specific care options","volume":"199","author":"Sanda","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2023.09.007_bib0023","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00066-020-01723-8","article-title":"Ultrahypofractionation of localized prostate cancer: Statement from the DEGRO working group prostate cancer","volume":"197","author":"Wolf","year":"2021","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.prro.2023.09.007_bib0024","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1097\/JU.0000000000000071","article-title":"Hypofractionated radiation therapy for localized prostate cancer: Executive summary of an ASTRO, ASCO and AUA evidence-based guideline","volume":"201","author":"Morgan","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.prro.2023.09.007_bib0025","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/S1470-2045(22)00517-4","article-title":"Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial","volume":"23","author":"Tree","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2023.09.007_bib0026","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2023.09.007_bib0027","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ijrobp.2018.06.008","article-title":"Patient reported outcomes in NRG Oncology RTOG 0938, evaluating two ultrahypofractionated regimens for prostate cancer","volume":"102","author":"Lukka","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.09.007_bib0028","first-page":"289","article-title":"Androgen suppression and radiation versus radiation alone for prostate cancer: A randomized trial","volume":"299","author":"D'Amico","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.prro.2023.09.007_bib0029","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2023.09.007_bib0030","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.eururo.2013.03.033","article-title":"A new risk classification system for therapeutic decision making with intermediate-risk prostate cancer patients undergoing dose-escalated external-beam radiation therapy","volume":"64","author":"Zumsteg","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2023.09.007_bib0031","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1200\/JCO.22.02390","article-title":"Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: Results of a phase III multi-institutional trial","volume":"41","author":"Krauss","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.09.007_bib0032","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199707313370502","article-title":"Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin","volume":"337","author":"Bolla","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2023.09.007_bib0033","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2023.09.007_bib0034","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1001\/jama.292.7.821","article-title":"6-month androgen suppression plus radiation therapy versus radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial","volume":"292","author":"D'Amico","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.prro.2023.09.007_bib0035","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(18)30757-5","volume":"20","author":"Denham","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2023.09.007_bib0036","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.eururo.2018.06.018","article-title":"Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized phase III trial","volume":"74","author":"Nabid","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2023.09.007_bib0037","article-title":"Duration of androgen deprivation therapy in high-risk prostate cancer: A randomized phase III trial","volume":"74","author":"Ghadjar","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2023.09.007_bib0038","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","article-title":"EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, diagnosis, and local treatment with curative intent","volume":"71","author":"Mottet","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.prro.2023.09.007_bib0039","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1470-2045(18)30893-3","article-title":"Androgen deprivation therapy in prostate cancer: New findings and questions for the future","volume":"20","author":"Sartor","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2023.09.007_bib0040","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: Results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2023.09.007_bib0041","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0140-6736(21)02759-8","article-title":"Racialised people in clinical guideline panels","volume":"399","author":"Persaud","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2023.09.007_bib0042","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ijrobp.2022.10.031","article-title":"Demographic trends among American Society for Radiation Oncology Clinical Practice Guideline Task Force participants from 2010 to 2022","volume":"116","author":"Kamran","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.09.007_bib0043","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jclinepi.2017.01.014","article-title":"GRADE equity guidelines 1: Considering health equity in GRADE guideline development: Introduction and rationale","volume":"90","author":"Welch","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.prro.2023.09.007_bib0044","unstructured":"American Society for Radiation Oncology Guideline Subcommittee. ASTRO Clinical Practice Guideline Methodology Guide. Accessed March 2, 2023.https:\/\/www.astro.org\/ASTRO\/media\/ASTRO\/Patient%20Care%20and%20Research\/PDFs\/ASTRO_GuidelineMethodology.pdf."},{"key":"10.1016\/j.prro.2023.09.007_bib0045","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncr.33225","article-title":"Reconciling outcomes for Black men with prostate cancer within and outside the Veterans Health Administration","volume":"127","author":"Deville","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2023.09.007_bib0046","first-page":"1","article-title":"Health disparities in prostate cancer and approaches to advance equitable care","volume":"42","author":"Washington","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.prro.2023.09.007_bib0047","first-page":"202","article-title":"Cancer statistics for African American\/Black people 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.prro.2023.09.007_bib0048","doi-asserted-by":"crossref","first-page":"4090","DOI":"10.1007\/s00261-020-02657-6","article-title":"Health disparities and inequities in the utilization of diagnostic imaging for prostate cancer","volume":"45","author":"Washington","year":"2020","journal-title":"Abdom Radiol (NY)"},{"key":"10.1016\/j.prro.2023.09.007_bib0049","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.32388","article-title":"Racial and ethnic disparities in the use of prostate magnetic resonance imaging following an elevated prostate-specific antigen test","volume":"4","author":"Abashidze","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.prro.2023.09.007_bib0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1439","article-title":"Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US","volume":"6","author":"Cooperberg","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.prro.2023.09.007_bib0051","doi-asserted-by":"crossref","first-page":"e719","DOI":"10.1016\/j.clgc.2018.01.018","article-title":"Active surveillance for prostate cancer: Are we failing Latino patients at a large safety net hospital?","volume":"16","author":"Ballas","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.prro.2023.09.007_bib0052","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.euo.2021.07.006","article-title":"Prostate cancer racial disparities: A systematic review by the Prostate Cancer Foundation Panel","volume":"5","author":"Mahal","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.prro.2023.09.007_bib0053","article-title":"Disparities in the utilization of radiation therapy for prostate cancer in the United States: A comprehensive review","volume":"7","author":"Gardner","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.prro.2023.09.007_bib0054","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1001\/jamaoncol.2019.0812","article-title":"Racial inequality in prostate cancer outcomes-socioeconomics, not biology","volume":"5","author":"Paller","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2023.09.007_bib0055","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","article-title":"Association of Black race with prostate cancer-specific and other-cause mortality","volume":"5","author":"Dess","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2023.09.007_bib0056","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1377\/hlthaff.2016.0158","article-title":"Achieving health equity: Closing the gaps in health care disparities, interventions, and research","volume":"35","author":"Purnell","year":"2016","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.prro.2023.09.007_bib0057","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ijrobp.2022.09.047","article-title":"Ensuring that health inequities and disparities are not exacerbated in the evolving oligometastatic treatment paradigm","volume":"114","author":"Alcorn","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2023.09.007_bib0058","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1200\/OP.22.00383","article-title":"Shorter radiation regimens and treatment noncompletion among patients with breast and prostate cancer in the United States: An analysis of racial disparities in access and quality","volume":"19","author":"Dee","year":"2023","journal-title":"JCO Oncol Pract"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850023002758?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850023002758?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T10:25:04Z","timestamp":1761819904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850023002758"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1879850023002758"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2023.09.007","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation Therapy Summary of the AUA\/ASTRO Guideline on Clinically Localized Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2023.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}